Multi-Agent Reinforcement Learning of Co-Adaptive Hip Exoskeleton Control (MARL-Exo) for Metabolic Energy Reduction

Practical Tips

Practical tips and how-to guidance will be added by our editorial team.

中文解读

中文解读待补充：本站将优先为睡眠改善、失眠治疗、助眠方法等高价值文章补充中文说明。

Article Summary

Objective: This study aims to determine whether a hip-exoskeleton policy trained in simulation, by co-adapting with a musculoskeletal human model under a metabolic-energy reward, reduces the metabolic cost of walking in new users without per-user tuning, and how mechanical-power shaping affects the learned assistance. Methods: We developed MARL-Exo, a multi-agent reinforcement learning framework in which a full-body human model (304 muscle actuators; randomized anatomy, gait, and speed) and a bilateral hip-exoskeleton policy are trained concurrently in two stages. The exoskeleton observes only delayed hip kinematics and its past commands; its reward includes muscle metabolic power from a physiologically based energetics model, alone (Metabolic) or with mechanical-power shaping (Metabolic + Power). The Metabolic policy was deployed and tested without retraining in eight healthy adults walking at 1.25 m/s, using indirect calorimetry. Results: In simulation, the Metabolic policy reduced modeled muscle metabolic power by 13.8% relative to no-device walking, versus 8.8% for Metabolic + Power. On hardware, MARL-Exo reduced net metabolic rate by 18.3 $\pm$ 6.6% relative to Passive in all eight participants. Relative to No-Exo, the mean reduction was 7.4 $\pm$ 10.0%; six participants more than offset the 13.1% device-wearing penalty, walking up to 24.2% below their No-Exo cost. Conclusion: A metabolically informed policy co-adapted in simulation transferred to users without per-user tuning and consistently reduced the metabolic cost of walking with the device, while explicit power shaping reduced the simulated benefit. Significance: Unlike per-user human-in-the-loop optimization, this approach yields a single population-level controller and allows assistance objectives to be screened in simulation before human testing.

Sources & References

• Original source
• Full article (PDF)

Comments